SCHEMBL29301488

SCHEMBL29301488

Cn1nc(Cl)c2cc(C(=O)O)ccc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 6/20 0.50
KDM4E B2RXH2 2/20 0.50
SLC22A12 Q96S37 3/20 0.47
HPGD P15428 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CPT1A P50416 2/20 0.43
CPT2 P23786 1/20 0.43
CPT1B Q92523 1/20 0.43
TSHR P16473 1/20 0.42
TEAD1 P28347 1/20 0.41
TEAD4 Q15561 1/20 0.41
TEAD2 Q15562 1/20 0.41
TEAD3 Q99594 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
CHRM4 P08173 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
TBXAS1 P24557 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189248 1.00 HCAR3 (0.50) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL29301489 0.87 ALDH1A1 (0.40) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL30040739 0.82 HCAR3 (0.55) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL23535727 0.82 HCAR3 (0.55) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL15970841 0.81 HCAR3 (0.55) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL4990562 0.81 HPGD (0.49) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL4989877 0.81 HPGD (0.52) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL14869360 0.81 HCAR3 (0.50) HCAR3KDM4ESLC22A12HPGDALDH1A1
SCHEMBL23559718 0.81 HCAR3 (0.50) HCAR3KDM4EHPGDALDH1A1CPT1A
SCHEMBL29960281 0.81 HCAR3 (0.50) HCAR3KDM4EHPGDALDH1A1CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
EP-4149945-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2023-03-22 EP disclosed
CN-115551864-A Substituted tricyclic amides, analogs thereof, and methods of using the same 爱彼特生物制药公司 2022-12-30 CN disclosed
WO-2021229302-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 HCAR3 388/4885KDM4E 1496/4885SLC22A12 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.